Skip to content
RVBA-JOHNSPrivate

Johnson & Johnson

US
Verified credentials
SBTi Validated1.5°C
no trajectory chart yet — needs at least one percent-reduction target with matching scope data

Headline intensities

·Values in USD ($)
Peer cohort: · lower is better
Revenue intensity
Carbon / $m revenue
tCO2e / $m revenue

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

Operational intensity
Carbon / $m OpEx
tCO2e / $m OpEx

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

Economic intensity
Carbon / $m EVIC
tCO2e / $m EVIC

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

Asset intensity
Carbon / $m PP&E + leased
tCO2e / $m PP&E

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

Climate action evidence

1 record · 1 source
Net-zero claim · FY2045 · In corporate strategy · nzt
"Path to our 2045 net zero ambition - • Moving as quickly as markets allow, continue to decarbonize our operations, products and value chain, including the use of low carbon technologies, fuels and materials • As needed, invest in carbon compensation and removal partnerships" Source: Climate Action Plan at-a-glance https://web.archive.org/web/20251118220244/https://www.jnj.com/our-societal-impact/global-environmental-sustainability/health-for-humanity-goals
Carbon credits retired
1 tCO2e
1 retirement · FY2022 · third-party verified
No self-reported carbon removals for FY2022.
By credit quality
  • Avoidance / reductions1 tCO2e(100%)
Retirements by year and credit class
2022
1tCO₂e
Avoidance
Renewable electricity
No third-party REC retirements on file and no self-reported renewable share disclosed.
Sources
  • · berkeley_voluntary_registry
Registry retirements are direct evidence; commitments are forward-looking pledges. EPA snapshot covers FY2019–FY2020.

Targets

Near-term

3 targets
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2Absolute20212030−44%1.5°Cinsufficient data
Scope 1 + 2 + 3Absolute20212030−44%In corporate strategyinsufficient data
Scope 320212028−80%insufficient data

Net zero

1 target
ScopeBaseTargetReductionAlignmentProgressStatus
Scope 1 + 2 + 320212045In corporate strategyabsolute-value target
Partial profile

We haven't fully researched Johnson & Johnson yet.

Request a full evidence-chained profile — we'll dig into their carbon, nature, social & water disclosure, find their facilities and sources, and email you when it's ready.

We’ll only use your email to notify you about this request.

Latest news· last 5 of 8

full news log →
  • Talc litigation reserve increased to ~$11.6B PV

    Cumulative incremental charge of approximately $5.0 billion recorded through Q4 2024 for talc matters. Total present value of reserve approximately $11.6 billion (nominal value ~$13.5 billion). Company pursuing prepackaged Chapter 11 via Red River Talc subsidiary.

    2024
  • Divested Acclarent

    Completed divestiture of Acclarent resulting in approximately $0.3 billion in proceeds and a $0.2 billion gain.

    2024
  • Acquired V-Wave (~$0.6B upfront)

    Completed acquisition of V-Wave Ltd, a heart failure treatment company, for $0.6B upfront with up to $1.1B in additional milestone payments. Recorded $0.5B IPR&D charge.

    2024
  • Acquired Proteologix (~$0.8B)

    Completed acquisition of Proteologix, a biotechnology company focused on bispecific antibodies for immune-mediated diseases.

    2024
  • Acquired Shockwave Medical (~$13.1B)

    Completed acquisition of Shockwave Medical Inc., a leading provider of intravascular lithotripsy (IVL) technology for treatment of calcified CAD/PAD, for $335.00 per share. Total enterprise value approximately $13.1 billion. Results included in MedTech segment.

    2024

Latest reporting year· 3 earlier years on Data-by-year tab

all years + ratios →

2025

reporting year
Financials
Revenue
OpEx
FTE
Market cap (FY-end)
Climate
Scope 1
Scope 2 (market)
Scope 2 (location)
Scope 3 total

Source documents· FY2025

all documents →
sustainability report2025
via manual upload · 0.7 MB
extractedOPEN PDF ↗